SCHEMBL15020756

SCHEMBL15020756

CCOCc1nn2c(-c3ccc(F)cc3)cc(N3CCCC3CO)nc2c1-c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 1/20 0.41
▸ SCN9A Q15858 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.36
▸ HPGD P15428 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ CRHR1 P34998 1/20 0.35
▸ ENPP2 Q13822 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ CHRM3 P20309 2/20 0.34
▸ ITGB2 P05107 1/20 0.33
▸ ICAM1 P05362 1/20 0.33
▸ ITGAL P20701 1/20 0.33
▸ EGLN2 Q96KS0 1/20 0.33
▸ BCL6 P41182 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ TP53 P04637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020887 0.93 FPR2 (0.42) FPR2SCN9AALDH1A1HPGDSMN1; SMN2
SCHEMBL15020888 0.93 FPR2 (0.42) FPR2SCN9AALDH1A1HPGDSMN1; SMN2
SCHEMBL15020926 0.92 FPR2 (0.36) FPR2SCN9AALDH1A1HPGDHSD17B10
SCHEMBL15020570 0.92 FPR2 (0.42) FPR2SCN9AALDH1A1HPGDSMN1; SMN2
SCHEMBL15021381 0.91 FPR2 (0.44) FPR2SCN9AALDH1A1HPGDSMN1; SMN2
SCHEMBL15020794 0.87 MEN1 (0.40) FPR2SCN9AALDH1A1CHRM3ITGB2
SCHEMBL15021006 0.86 TP53 (0.46) FPR2SCN9AALDH1A1HPGDHSD17B10
SCHEMBL15021293 0.85 FPR2 (0.37) FPR2SCN9AALDH1A1HPGDSMN1; SMN2
SCHEMBL15020764 0.84 FPR2 (0.37) FPR2SCN9ACRHR1CHRM3ITGB2
SCHEMBL15020543 0.84 FPR2 (0.37) FPR2SCN9ACRHR1CHRM3ITGB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US claimed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 FPR2 2908/4885SCN9A 615/4885ALDH1A1 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback